1-Benzyl-6-chloro-1h-indole-3-carboxylic acid | 921195-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Benzyl-6-chloro-1h-indole-3-carboxylic acid
• 英文别名: 1-benzyl-6-chloroindole-3-carboxylic acid
• CAS: 921195-00-8
• 化学式: C₁₆H₁₂ClNO₂
• 分子量: 285.72
• InChiKey: AVOFWCDDJJHLPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives
  申请人：Bissantz Caterina

  公开号：US20070021463A1

  公开（公告）日：2007-01-25

  The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 7 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephritic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.

  本发明涉及Indol-3-yl-carbonyl-piperidin-benzoimidazol衍生物，其作为V1a受体拮抗剂，并由以下式表示：其中残基R1至R7如本文所定义。本发明还涉及含有这种化合物的药物组合物，其用于治疗经期疼痛、高血压、慢性心力衰竭、抗利尿素的不当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症，以及其制备方法。
• INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20100256140A1

  公开（公告）日：2010-10-07

  The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 7 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephritic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.

  本发明涉及一种Indol-3-yl-carbonyl-piperidin-benzoimidazol衍生物，其作为V1a受体拮抗剂，并由公式I所表示：其中残基R1至R7的定义如本文所述。本发明还涉及包含此类化合物的制药组合物，其用于治疗痛经、高血压、慢性心力衰竭、抗利尿激素不适当分泌、肝硬化、肾病综合征、强迫性障碍、焦虑和抑郁症，并提供其制备方法。
• INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1912976A1

  公开（公告）日：2008-04-23
• INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1912976B1

  公开（公告）日：2008-11-12
• US7803815B2
  申请人：——

  公开号：US7803815B2

  公开（公告）日：2010-09-28